By Mrinalika Roy and Patrick Wingrove (Reuters) -Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's new national priority voucher, suggesting it is a strong candidate for a significantly accelerated approval review. Lilly said it will submit its review package for the pill, orforglipron, to the FDA this quarter, adding the agency will decide on the approval process. In June, the FDA unveiled a program under which its commissioner ca ...

Sign up for Yahoo Finance Daily Movers (Reuters) -Eli Lilly (LLY) raised its full-year profit and revenue forecast on Thursday as strong appetite for its widely popular weight-loss and diabetes drugs Zepbound and Mounjaro helped it beat third-quarter earnings estimates. The company shares rose 2% in early morning trading on Thursday. Lilly competes with Novo Nordisk for the top spot in the weight-loss drug market, which is poised to reach $150 billion by the end of the decade. Investors have been keenly awa ...